Nucleotide Metabolism: Biosynthesis, Regulation, and Clinical Relevance

Nucleotide Metabolism

Introduction

Nucleotides are essential biomolecules that serve as the building blocks of nucleic acids (DNA and RNA), energy carriers, and signaling molecules. Their metabolism involves complex biosynthetic and degradation pathways, tightly regulated to maintain cellular function and genomic integrity.

Revision of Nucleotide Structure

Nucleosides and Nucleotides

• Nucleoside: Consists of a nitrogenous base (purine or pyrimidine) linked to a sugar (ribose or deoxyribose).

• Nucleotide: A nucleoside with one or more phosphate groups attached to the sugar.

General Structure:

• Pyrimidines: Cytosine, Thymine (DNA only), Uracil (RNA only)

• Purines: Adenine and Guanine (both DNA and RNA)

Key distinction: Purines have a double-ring structure, while pyrimidines have a single-ring structure.

Biosynthesis of Nucleotides

5-Phosphoribosyl 1-pyrophosphate (PRPP)

• Both purine and pyrimidine biosynthesis require PRPP as a ribose-phosphate donor.

• PRPP is synthesized from ribose 5-phosphate and ATP by the enzyme PRPP synthetase.

Pyrimidine Biosynthesis

• The pyrimidine ring is synthesized first, then attached to PRPP.

• Key precursors: Bicarbonate, NH₃, Aspartate

• UMP (uridine monophosphate) is synthesized in 6 steps, involving a bifunctional enzyme (UMP synthase).

• Deficiency in UMP synthase leads to hereditary orotic aciduria (high orotic acid levels).

Pathway Overview:

• Carbamoyl phosphate + Aspartate → Pyrimidine ring → UMP → UDP → UTP → CTP

• dUMP is converted to dTMP by thymidylate synthase (requires folate derivatives).

Regulation of Pyrimidine Biosynthesis

• High PRPP activates pyrimidine biosynthesis.

• High UMP, UDP, and UTP inhibit pyrimidine biosynthesis (feedback inhibition).

Deoxyribonucleotide Synthesis

• Deoxyribonucleotides (dNDPs) are produced from ribonucleotides (NDPs) by ribonucleotide reductase.

• Ribonucleotide reductase is tightly regulated to ensure balanced dNTP pools for DNA synthesis.

Formation of dTMP from dUMP

• dUMP is methylated to dTMP by thymidylate synthase, using N5,N10-methylene tetrahydrofolate as a methyl donor.

• Dihydrofolate is regenerated to tetrahydrofolate by dihydrofolate reductase (requires NADPH).

Anticancer Drugs Targeting dTMP Synthesis

• Thymidylate synthase inhibitors (e.g., 5-fluorouracil) and dihydrofolate reductase inhibitors (e.g., methotrexate, aminopterin) block dTMP synthesis, impeding DNA replication in rapidly dividing cells.

• Trimethoprim is a bacterial DHFR inhibitor (antibiotic).

Purine Biosynthesis

• The purine ring is built stepwise on PRPP through a pathway involving 11 enzymes.

• Key precursors: Glycine, Glutamine, Aspartate, CO₂, N10-formyl-tetrahydrofolate

• The first purine nucleotide formed is IMP (inosine monophosphate), which is then converted to AMP and GMP.

IMP base is called hypoxanthine.

Regulation of Purine Biosynthesis

• High PRPP activates the pathway.

• High AMP, GMP, IMP, and ADP inhibit the pathway (feedback inhibition).

Purine Salvage Pathways

• Purines can be recycled by attaching them to PRPP via specific enzymes:

Enzyme	Reaction
Adenine phosphoribosyltransferase (APRT)	Adenine + PRPP → AMP + PPi
Hypoxanthine-guanine phosphoribosyltransferase (HGPRT)	Hypoxanthine + PRPP → IMP + PPi Guanine + PRPP → GMP + PPi

Lesch-Nyhan Syndrome

• Caused by defects in HGPRT (X-linked, mostly in males).

• Symptoms: Poor coordination, intellectual disability, self-mutilation, and gout (due to excess uric acid).

• Defective salvage leads to increased de novo purine synthesis and uric acid accumulation.

Nucleotide Degradation

Overview

• Purine nucleotides are degraded to uric acid.

• Pyrimidine nucleotides are degraded to malonyl-CoA and ribose-1-phosphate.

Purine Degradation Pathway

• AMP/GMP → Inosine/Guanosine → Hypoxanthine/Xanthine → Uric acid

• Uric acid is excreted in urine; excess leads to gout.

Gout

• Gout is caused by elevated uric acid in blood/tissues, leading to joint inflammation and uric acid crystal deposition.

• Kidneys may also be affected by uric acid deposition.

Treatment of Gout

• Allopurinol (xanthine oxidase inhibitor) is used to treat gout by reducing uric acid production.

• Allopurinol is converted to oxypurinol, which remains bound to xanthine oxidase, inhibiting its activity.

Summary Table: Key Steps in Nucleotide Metabolism

Process	Main Intermediates	Key Enzymes	Clinical Relevance
Pyrimidine Biosynthesis	UMP, UDP, UTP, CTP, dTMP	Carbamoyl phosphate synthetase II, UMP synthase, Thymidylate synthase	Orotic aciduria, Chemotherapy targets
Purine Biosynthesis	IMP, AMP, GMP	PRPP synthetase, Amidophosphoribosyltransferase	Lesch-Nyhan syndrome, Gout
Degradation	Uric acid, Malonyl-CoA	Xanthine oxidase	Gout, Allopurinol therapy

Key Equations

• $\text{Adenine} + \text{PRPP} \longrightarrow \text{AMP} + \text{PP}_i$

• $\text{Hypoxanthine} + \text{PRPP} \longrightarrow \text{IMP} + \text{PP}_i$

• $\text{Guanine} + \text{PRPP} \longrightarrow \text{GMP} + \text{PP}_i$

Clinical Applications and Disease Associations

• Anticancer drugs target nucleotide synthesis (e.g., methotrexate, 5-fluorouracil).

• Lesch-Nyhan syndrome and gout are metabolic disorders linked to purine metabolism.

• Allopurinol is a key treatment for gout, reducing uric acid levels.

Additional info: This summary integrates core concepts from nucleotide metabolism relevant to genetics, including biosynthesis, regulation, salvage, degradation, and clinical implications.